Effect of Male Circumcision on HIV Incidence (ANRS 1265)
HIV Infections, Herpes Genitalis, Venereal Diseases
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring HIV, Male circumcision, Prevention, HSV-2, Africa, Sexual behavior
Eligibility Criteria
Inclusion Criteria: Uncircumcised men aged 18-24 years Be in good general condition with normal physical and genital examinations Consenting to participate in the trial and to sign an informed consent Consenting to randomization of the medicalized circumcision schedule (performed at the beginning of study for the treated group, optional at the end of study for the control group) Consenting to avoid sexual contact (except with condom protection) during the 6 weeks following the medicalized circumcision Consenting to blood tests at M.0, M.3, M.12 and M.21 tested for HIV, HSV-2 and syphilis. Exclusion Criteria: Men with AIDS Men with contraindication for circumcision Men thinking of moving away from the trial sites within the 21 months following inclusion Men with clinical sexually transmitted diseases (STDs) (those men could be included after treatment)
Sites / Locations
- MC Centre